Analysis Of Income And Expense [Abstract]

Innate Pharma - Filing #882171

Concept	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue	—	—	24 703 EUR	—	69 773 EUR	—	—
Material income and expense [abstract]
Research and development expense	—	—	47 004 EUR	—	49 708 EUR	—	—
Finance income (cost)	—	—	2 347 EUR	—	1 908 EUR	—	—
Selling, general and administrative expense [abstract]
Selling, general and administrative expense	—	—	25 524 EUR	—	18 986 EUR	—	—
Operating expense	—	—	72 528 EUR	—	68 694 EUR	—	—
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	—	483,000 EUR	483,000 EUR	805,000 EUR	222,000 EUR	—	1 027 EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	52 809 EUR	101,000 EUR	52 708 EUR	805,000 EUR	63 962 EUR	63 984 EUR	827,000 EUR